文献速递临床试验与 GCP基础与转化研究

大麻二酚与安慰剂作为早期精神病辅助治疗的对照研究:随机对照试验研究方案

Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial.
PubMed 文献 · Trials · 2023-11-30

本研究为一项为期8周的双盲优效性随机对照试验,计划纳入120例早期精神病患者,在现有治疗基础上随机加用大麻二酚(CBD)1000 mg或安慰剂,主要结局为症状与神经认知,并探索神经激素、炎症、进食行为、信息处理及疗效预测因素。

要点

  • 120例早期精神病患者随机接受CBD 1000 mg或安慰剂辅助治疗,疗程8周。
  • 主要结局为症状与神经认知,次要结局包括神经激素、炎症、进食行为和信息处理。
  • 试验将考察CBD疗效的预测因素、调节因素与中介因素,以助个体化治疗。

核心结论

  • 作者假设CBD可改善症状与神经认知,并改善神经激素、炎症、进食行为和信息处理等次要结局指标。
  • 作者认为更好地了解哪些个体可能对CBD应答,可指导治疗规划并实现个体化治疗。

研究设计与样本

  • 一项为期8周、双盲、优效性随机对照试验,共120例早期精神病患者随机接受CBD 1000 mg或安慰剂作为现有治疗的辅助。
  • 主要结局指标为症状与神经认知。

主要发现

  • 原文为研究方案,尚未报告试验结果。
  • 作者指出,越来越多证据显示CBD对阳性精神病性症状有效,可能对阴性症状和神经认知症状也有效,且与其他精神药物相比耐受性良好。
  • 作者提到,加州大学圣地亚哥分校认知评估与风险评估(CARE)早期精神病治疗项目的患者自行使用CBD,并报告压力、焦虑和应对症状能力主观改善(为轶事性观察)。
  • 作者指出,近期证据提示CBD可能降低压力和促炎生物标志物水平。
  • 作者指出,CBD的神经生理效应已在精神病动物模型中研究,显示信息处理改善,但尚无早期精神病患者中的研究。

局限性

  • 作者指出,大麻二酚对精神病产生治疗作用的机制尚不清楚。
  • 作者指出,CBD的神经生理效应仅在精神病动物模型中研究,尚无早期精神病患者中的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psychotic disorders are a leading cause of disability in young adults. Antipsychotics have been the primary intervention for psychosis for over 60 years, and yet, we have made little progress in treating negative symptoms, neurocognition, and functional disability. There is growing evidence that cannabidiol (CBD) is effective in treating positive psychotic symptoms, possibly also negative and neurocognitive symptoms, and moreover is well tolerated compared to other psychotropic medications. Anecdotally, patients participating in the Cognitive Assessment and Risk Evaluation (CARE) Early Psychosis Treatment Program at the University of California, San Diego, are self-administering CBD and report subjective improvement in stress, anxiety, and ability to cope with symptoms. The overarching aim of the trial is to explore the effectiveness of CBD augmentation on symptoms and neurocognition in early psychosis while also exploring the mechanism of action of CBD and predictors of response to treatment. The mechanism by which cannabidiol has a therapeutic effect on psychosis is poorly understood. Recent evidence has suggested that CBD may reduce stress and pro-inflammatory biomarker levels. Endocannabinoids also have powerful roles in eating behavior, reward, and mood, indicating these neurotransmitters may play a role in reducing hyperphagia and metabolic abnormalities that are present early in the course of psychotic illness and exacerbated by antipsychotic medication. The neurophysiological effects of CBD have been studied in animal models of psychosis that show improvements in information processing in response to CBD, but there are no studies in individuals with early psychosis. METHOD: A total of 120 individuals in the early stages of psychosis will be randomized to 1000 mg of CBD versus placebo as an adjunct to existing treatment in a 8-week, double-blind superiority randomized control trial. The primary outcome measures are symptoms and neurocognition. DISCUSSION: We hypothesized that CBD will improve symptoms and neurocognition as well as secondary outcome measures of neurohormones, inflammation, eating behaviors, and information processing. Importantly, predictors, moderators, and mediators of the CBD effects will be examined. A better understanding of which individuals are likely to respond to CBD can inform treatment planning and personalize treatment. TRIAL REGISTRATION: ClinicalTrials.gov NCT04411225. Registered on June 2, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Dixon T, Cadenhead KS. Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial. Trials. 2023. PMID: 38037108. doi:10.1186/s13063-023-07789-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。